COVID-19 and colchicine - Can we weather the storm?
*Corresponding Author:
Copyright: © 2020 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
We read with interest the study published by Cavalli et al. which showed that blocking interleukin-1 (IL-1) with high-dose of anakinra was safe and resulted in clinical improvement in 72% of patients with ARDS managed with non-invasive ventilation outside the intensive care unit [1]. Anakinra is a recombinant human IL-1 receptor antagonist that binds to the IL-1 receptor and block signal transduction. It is approved by FDA for rheumatoid arthritis and autoinflammatory syndromes treatment.
